BRIEF-Cerulean Pharma estimates cash, cash equivalents as of June 30,
April 17, 2017 at 16:45 PM EDT
* Cerulean Pharma-estimates cash, cash equivalents as of june 30, assuming has not consummated transactions under novartis apa or dar*pa, to be $4 million-$6 million
